EP3247381A4 - Méthodes de traitement de l'inflammation à l'aide de tgf-bêta - Google Patents

Méthodes de traitement de l'inflammation à l'aide de tgf-bêta Download PDF

Info

Publication number: EP3247381A4
Authority: EP; European Patent Office
Prior art keywords: tgf; beta; methods; treating inflammation; inflammation
Prior art date: 2015-01-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP16740836.8A

Other languages

German (de)

English (en)

Other versions

EP3247381A1 (fr

Inventor

Brett CASEBOLT

Ronald E. Strohbehn

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Puretein Bioscience LLC

Original Assignee

Puretein Bioscience LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-01-23

Filing date

2016-01-22

Publication date

2018-08-01

2016-01-22 Application filed by Puretein Bioscience LLC filed Critical Puretein Bioscience LLC

2017-11-29 Publication of EP3247381A1 publication Critical patent/EP3247381A1/fr

2018-08-01 Publication of EP3247381A4 publication Critical patent/EP3247381A4/fr

Status Withdrawn legal-status Critical Current

Links

206010061218 Inflammation Diseases 0.000 title 1
230000004054 inflammatory process Effects 0.000 title 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Dermatology (AREA)
Virology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Mycology (AREA)
Nutrition Science (AREA)
Polymers & Plastics (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Developmental Biology & Embryology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

EP16740836.8A 2015-01-23 2016-01-22 Méthodes de traitement de l'inflammation à l'aide de tgf-bêta Withdrawn EP3247381A4 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562106855P	2015-01-23	2015-01-23
US201562110816P	2015-02-02	2015-02-02
PCT/US2016/014526 WO2016118866A1 (fr)	2015-01-23	2016-01-22	Méthodes de traitement de l'inflammation à l'aide de tgf-bêta

Publications (2)

Publication Number	Publication Date
EP3247381A1 EP3247381A1 (fr)	2017-11-29
EP3247381A4 true EP3247381A4 (fr)	2018-08-01

Family

ID=56417809

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP16740836.8A Withdrawn EP3247381A4 (fr)	2015-01-23	2016-01-22	Méthodes de traitement de l'inflammation à l'aide de tgf-bêta

Country Status (3)

Country	Link
US (1)	US20180271943A1 (fr)
EP (1)	EP3247381A4 (fr)
WO (1)	WO2016118866A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN111655253A (zh)	2018-01-09	2020-09-11	杨百翰大学	用于用汉黄芩素治疗疼痛的组合物和方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007007095A2 (fr) *	2005-07-12	2007-01-18	Renovo Ltd	Compositions pharmaceutiques
US20080031969A1 (en) *	2004-12-09	2008-02-07	Christina Juneau	Composition for treating psoriasis
WO2012129330A1 (fr) *	2011-03-23	2012-09-27	Option Pharmaceutical, Llc	Cytokine ciblée pour le traitement de maladies musculosquelettiques
US20130280344A1 (en) *	2005-09-27	2013-10-24	Tissuetech, Inc.	Amniotic membrane preparations and purified compositions and anti-inflammation methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7585537B2 (en) *	2004-05-03	2009-09-08	Leprino Foods Company	Cheese and methods of making such cheese
EP2164515A4 (fr) *	2007-06-11	2011-04-27	Advitech Inc	Procédé de traitement d'eczéma atopique
US20130345113A1 (en) *	2011-07-13	2013-12-26	Ronald E. Strohbehn	Method of Use of Activated Functional Proteins to Improve Animal Health

2016
- 2016-01-22 EP EP16740836.8A patent/EP3247381A4/fr not_active Withdrawn
- 2016-01-22 WO PCT/US2016/014526 patent/WO2016118866A1/fr not_active Ceased
- 2016-01-22 US US15/544,940 patent/US20180271943A1/en not_active Abandoned

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080031969A1 (en) *	2004-12-09	2008-02-07	Christina Juneau	Composition for treating psoriasis
WO2007007095A2 (fr) *	2005-07-12	2007-01-18	Renovo Ltd	Compositions pharmaceutiques
US20130280344A1 (en) *	2005-09-27	2013-10-24	Tissuetech, Inc.	Amniotic membrane preparations and purified compositions and anti-inflammation methods
WO2012129330A1 (fr) *	2011-03-23	2012-09-27	Option Pharmaceutical, Llc	Cytokine ciblée pour le traitement de maladies musculosquelettiques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
See also references of WO2016118866A1 *
SUMIYOSHI K ET AL: "Transforming growth factor-beta1 suppresses atopic dermatitis-like skin lesions in NC/Nga mice", CLINICAL & EXPERIMENTAL ALLERGY : JOURNAL OF THE BRITISH SOCIETY FOR ALLERGY AND CLINICAL IMMUNO, WILEY INTERSCIENCE, UK, vol. 32, no. 2, 1 February 2002 (2002-02-01), pages 309 - 314, XP008125328, ISSN: 0954-7894, DOI: 10.1046/J.1365-2222.2002.01221.X *
VAN DER KRAAN P M ET AL: "TGF-beta signaling in chondrocyte terminal differentiation and osteoarthritis", OSTEOARTHRITIS AND CARTILAGE, BAILLIERE TINDALL, LONDON, GB, vol. 17, no. 12, 1 December 2009 (2009-12-01), pages 1539 - 1545, XP026763639, ISSN: 1063-4584, [retrieved on 20090626], DOI: 10.1016/J.JOCA.2009.06.008 *

Also Published As

Publication number	Publication date
US20180271943A1 (en)	2018-09-27
WO2016118866A1 (fr)	2016-07-28
EP3247381A1 (fr)	2017-11-29

Legal Events

Date	Code	Title	Description
2017-10-27	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2017-11-29	17P	Request for examination filed	Effective date: 20170810
2017-11-29	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2017-11-29	AX	Request for extension of the european patent	Extension state: BA ME
2018-05-02	DAV	Request for validation of the european patent (deleted)
2018-05-02	DAX	Request for extension of the european patent (deleted)
2018-08-01	A4	Supplementary search report drawn up and despatched	Effective date: 20180703
2018-08-01	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 35/20 20060101ALI20180627BHEP Ipc: A61K 47/10 20170101ALI20180627BHEP Ipc: A61P 19/02 20060101ALI20180627BHEP Ipc: A61K 9/06 20060101ALI20180627BHEP Ipc: A61P 17/00 20060101ALI20180627BHEP Ipc: A61K 38/18 20060101AFI20180627BHEP Ipc: A23L 33/10 20160101ALI20180627BHEP Ipc: A61P 31/22 20060101ALI20180627BHEP Ipc: A61P 17/06 20060101ALI20180627BHEP Ipc: A61K 9/00 20060101ALI20180627BHEP Ipc: A23L 33/19 20160101ALI20180627BHEP Ipc: A61P 43/00 20060101ALI20180627BHEP Ipc: A61P 17/10 20060101ALI20180627BHEP
2019-07-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2019-08-14	18D	Application deemed to be withdrawn	Effective date: 20190131

Publication	Publication Date	Title
EP3384881A4 (fr)	2019-01-02	Dispositif d'irradiation
EP3332717A4 (fr)	2019-08-28	Dispositif de traitement
EP3352673A4 (fr)	2018-12-05	Ensembles radio-absorbants
EP3211743A4 (fr)	2018-01-24	Procédé de commutation d'îlot à réseau
EP3229808A4 (fr)	2018-03-07	Méthodes de traitement d'infections fongiques
EP3341330A4 (fr)	2018-09-12	Procédés pour le traitement de matériaux contenant du lithium
EP3057993A4 (fr)	2017-09-13	Procédés de traitement d'états associés à une activation du complément dépendant de masp-2
EP3171878A4 (fr)	2018-03-14	Méthodes de traitement de paramyxovirus
EP3271628A4 (fr)	2018-12-05	Dispositif d'arrêt
EP3220916A4 (fr)	2018-07-11	Méthode de traitement du cancer
EP3206688A4 (fr)	2018-06-13	Méthode de traitement du cancer
EP3158133A4 (fr)	2018-01-24	Appareil d'atténuation de l'énergie d'impact
EP3110509A4 (fr)	2017-11-01	Méthode de traitement du cancer
EP3268087A4 (fr)	2018-08-29	Méthodes de traitement du cancer par des inhibiteurs de ror gamma
EP3189074A4 (fr)	2018-06-20	Compositions et méthodes pour traiter et prévenir l'inflammation
EP3188722A4 (fr)	2018-06-13	Méthodes de traitement d'infections à protozoaires
EP3259510A4 (fr)	2018-10-31	Appareil solénoïde
EP3271014A4 (fr)	2019-03-06	Dispositif de photothérapie
EP3264008A4 (fr)	2018-10-10	Dispositif de congélation
EP3319401A4 (fr)	2018-06-13	Dispositif gradateur
EP3194025A4 (fr)	2018-05-23	Méthodes de prévention ou de traitement de l'arthrose
EP3366758A4 (fr)	2019-05-08	Dispositif de traitement de cellules
EP3345996A4 (fr)	2019-03-06	Procédé de production de -glutamyl-valyl-glycine
EP3319400A4 (fr)	2018-07-11	Dispositif gradateur
EP3290844A4 (fr)	2018-10-31	Dispositif de traitement thermique